BioCentury
ARTICLE | Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

December 31, 2020 1:53 AM UTC

Covaxx licenses COVID vaccine to Aurobindo
Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) gained exclusive rights from the Covaxx unit of United Biomedical Inc. to develop and market UB-612 in India and to the United Nations Children’s Fund (UNICEF) and non-exclusive rights in other select emerging and developing markets. Covaxx will supply the bulk product for the peptide COVID-19 vaccine, and Aurobindo will manufacture finished doses in Hyderabad; financial terms are undisclosed. Aurobindo has an initial capacity of 220 million doses and is scaling up to have nearly 480 million doses by June 2021.

Moderna, Recipharm deal for COVID vaccine manufacturing
Moderna Inc. (NASDAQ:MRNA) and CDMO Recipharm AB (SSE:RECI B) partnered to support formulation and fill-finish part of the mRNA-1273 supply outside the U.S., where they expect supply to start in early 2021. Deal terms were undisclosed...